<SEC-DOCUMENT>0001206774-18-003083.txt : 20181101
<SEC-HEADER>0001206774-18-003083.hdr.sgml : 20181101
<ACCEPTANCE-DATETIME>20181101161517
ACCESSION NUMBER:		0001206774-18-003083
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20181101
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20181101
DATE AS OF CHANGE:		20181101

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			GERON CORP
		CENTRAL INDEX KEY:			0000886744
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				752287752
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-20859
		FILM NUMBER:		181153925

	BUSINESS ADDRESS:	
		STREET 1:		149 COMMONWEALTH DRIVE
		STREET 2:		SUITE 2070
		CITY:			MENLO PARK
		STATE:			CA
		ZIP:			94025
		BUSINESS PHONE:		6504737700

	MAIL ADDRESS:	
		STREET 1:		149 COMMONWEALTH DRIVE
		STREET 2:		SUITE 2070
		CITY:			MENLO PARK
		STATE:			CA
		ZIP:			94025

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GERON CORPORATION
		DATE OF NAME CHANGE:	19960521
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>geron33139020-8k.htm
<DESCRIPTION>CURRENT REPORT
<TEXT>

<HTML>
<HEAD>
   <TITLE></TITLE>
</HEAD>

<BODY bgcolor="#ffffff">


<P style="TEXT-ALIGN: center"><B><FONT size=2 face="Times New Roman">UNITED STATES<BR></FONT></B><B><FONT size=2 face="Times New Roman">SECURITIES AND EXCHANGE COMMISSION <BR>WASHINGTON, D.C. 20549 <BR>___________ </FONT></B></P>
<P style="TEXT-ALIGN: center"><B><FONT size=2 face="Times New Roman">FORM 8-K</FONT></B></P>
<P style="TEXT-ALIGN: center"><B><FONT size=2 face="Times New Roman">CURRENT REPORT<BR></FONT></B><B><FONT size=2 face="Times New Roman">PURSUANT TO SECTION 13 OR 15(d) OF THE <BR>SECURITIES EXCHANGE ACT OF 1934</FONT></B></P>
<P style="TEXT-ALIGN: center"><FONT size=2 face="Times New Roman">Date of Report (Date of earliest event reported): </FONT><B><FONT size=2 face="Times New Roman">November 1, 2018</FONT></B></P>
<P style="TEXT-ALIGN: center"><B><FONT size=2 face="Times New Roman">&nbsp;GERON CORPORATION<BR></FONT></B><FONT size=2 face="Times New Roman">(Exact name of registrant as specified in its charter)</FONT></P>
<TABLE style="LINE-HEIGHT: 14pt; BORDER-COLLAPSE: COLLAPSE" cellSpacing=0 cellPadding=0 width="100%" border=0>

<TR vAlign=bottom>
   <TD width="33%" noWrap align=center><B><FONT size=2 face="Times New Roman">Delaware</FONT></B></TD>
   <TD width="33%" noWrap align=center><B><FONT size=2 face="Times New Roman">0-20859</FONT></B></TD>
   <TD width="33%" noWrap align=center><B><FONT size=2 face="Times New Roman">75-2287752</FONT></B></TD></TR>
<TR vAlign=bottom>
   <TD width="33%" noWrap align=center><FONT size=2 face="Times New Roman">(State or other jurisdiction</FONT></TD>
   <TD width="33%" noWrap align=center><FONT size=2 face="Times New Roman">(Commission File Number)</FONT></TD>
   <TD width="33%" noWrap align=center><FONT size=2 face="Times New Roman">(IRS Employer</FONT></TD></TR>
<TR vAlign=bottom>
   <TD width="33%" noWrap align=center><FONT size=2 face="Times New Roman">of incorporation)</FONT></TD>
   <TD width="33%" noWrap align=center></TD>
   <TD width="33%" noWrap align=center><FONT size=2 face="Times New Roman">Identification No.)</FONT></TD></TR></TABLE>

<P style="TEXT-ALIGN: center"><B><FONT size=2 face="Times New Roman">149 COMMONWEALTH DRIVE, SUITE 2070 <BR>MENLO PARK, CALIFORNIA 94025<BR></FONT></B><FONT size=2 face="Times New Roman">(Address of principal executive offices, including zip
code)</FONT></P>
<P style="TEXT-ALIGN: center"><B><FONT size=2 face="Times New Roman">(650) 473-7700<BR></FONT></B><FONT size=2 face="Times New Roman">(Registrant&#8217;s telephone number, including area code)</FONT></P>
<P style="TEXT-ALIGN: center"><B><FONT size=2 face="Times New Roman">N/A<BR></FONT></B><FONT size=2 face="Times New Roman">(Former name or former address, if changed since last report)</FONT></P>
<P style="TEXT-ALIGN: left"><FONT size=2 face="Times New Roman">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</FONT></P>
<DIV>

<TABLE style="WIDTH: 100%" cellSpacing=0 cellPadding=0 border=0>



<TR>

   <TD style="WIDTH: 1%; VERTICAL-ALIGN: top; TEXT-ALIGN: left"><FONT size=2 face="Times New Roman">&#9744;</FONT></TD>

   <TD width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>

   <TD width="98%"><FONT size=2 face="Times New Roman">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</FONT></TD></TR>

<TR>

   <TD style="VERTICAL-ALIGN: top; TEXT-ALIGN: left">&nbsp;</TD>

   <TD>&nbsp;</TD>

   <TD>&nbsp;</TD></TR>

<TR>

   <TD style="WIDTH: 1%; VERTICAL-ALIGN: top; TEXT-ALIGN: left"><FONT size=2 face="Times New Roman">&#9744;</FONT></TD>

   <TD width="1%"></TD>

   <TD width="98%"><FONT size=2 face="Times New Roman">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</FONT></TD></TR>

<TR>

   <TD style="VERTICAL-ALIGN: top; TEXT-ALIGN: left">&nbsp;</TD>

   <TD>&nbsp;</TD>

   <TD>&nbsp;</TD></TR>

<TR>

   <TD style="WIDTH: 1%; VERTICAL-ALIGN: top; TEXT-ALIGN: left"><FONT size=2 face="Times New Roman">&#9744;</FONT></TD>

   <TD width="1%"></TD>

   <TD width="98%"><FONT size=2 face="Times New Roman"><FONT size=2 face="Times New Roman">Pre</FONT>-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-<FONT size=2 face="Times New Roman">2<FONT size=2 face=
"Times New Roman">(b))</FONT></FONT> </FONT></TD></TR>

<TR>

   <TD style="VERTICAL-ALIGN: top; TEXT-ALIGN: left">&nbsp;</TD>

   <TD>&nbsp;</TD>

   <TD>&nbsp;</TD></TR>

<TR>

   <TD style="WIDTH: 1%; VERTICAL-ALIGN: top; TEXT-ALIGN: left"><FONT size=2 face="Times New Roman">&#9744;</FONT></TD>

   <TD width="1%"></TD>

   <TD width="98%"><FONT size=2 face="Times New Roman"><FONT size=2 face="Times New Roman">Pre</FONT>-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-<FONT size=2 face="Times New Roman">4<FONT size=2 face=
"Times New Roman">(c))</FONT></FONT></FONT></TD></TR></TABLE></DIV>

<P style="TEXT-ALIGN: left"><FONT size=2 face="Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the
Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</FONT></P>

<P style="TEXT-ALIGN: left"><FONT size=2 face="Times New Roman">Emerging growth company <FONT size=2 face="Times New Roman">&#9744;</FONT></FONT><FONT size=2 face="Times New Roman"></FONT></P>

<P style="TEXT-ALIGN: left"><FONT size=2 face="Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.&nbsp;<FONT size=2 face="Times New Roman">&#9744;</FONT></FONT></P>
<HR align=center SIZE=2 width="100%" noShade>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV>


<P style="TEXT-ALIGN: left"><B><FONT size=2 face="Times New Roman">Item 2.02 Results of Operations and Financial Condition</FONT></B></P>
<P STYLE="text-align: left; text-indent: 15pt"><FONT size=2 face="Times New Roman">Geron Corporation (the &#8220;Company&#8221;) is furnishing this information under Item 2.02 of Form 8-K.</FONT></P>
<P STYLE="text-align: left; text-indent: 15pt"><FONT size=2 face="Times New Roman">The information in this Current Report, including Exhibit 99.1, is being furnished and shall not be deemed &#8220;filed&#8221; for the purposes of Section 18 of the Securities Exchange Act
of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that section. The information in this Current Report, including Exhibit 99.1, shall not be incorporated by reference into any registration statement or other
document filed pursuant to the Securities Act of 1933, as amended, or the Exchange Act.</FONT></P>
<P STYLE="text-align: left; text-indent: 15pt"><FONT size=2 face="Times New Roman">On November 1, 2018, the Company issued a press release announcing its financial results for the three and nine months ended September 30, 2018. A copy of the press release is attached as
Exhibit 99.1.</FONT></P>
<P style="TEXT-ALIGN: left"><B><FONT size=2 face="Times New Roman">Item 9.01 Financial Statements and Exhibits</FONT></B></P>
<P STYLE="text-align: left; text-indent: 15pt"><FONT size=2 face="Times New Roman">(d) Exhibits</FONT></P>
<DIV align=right>
<TABLE style="WIDTH: 95%; LINE-HEIGHT: 14pt; BORDER-COLLAPSE: COLLAPSE" cellSpacing=0 cellPadding=0 border=0>

<TR vAlign=bottom>
   <TD style="BORDER-BOTTOM: #000000 1pt solid" width="3%" noWrap align=center><B><FONT size=2 face="Times New Roman">Exhibit No.</FONT></B></TD>
   <TD style="BORDER-BOTTOM: #000000 1pt solid" width="1%" noWrap align=left>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
   <TD style="BORDER-BOTTOM: #000000 1pt solid" width="95%" noWrap align=left><B><FONT size=2 face="Times New Roman">Description</FONT></B></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
   <TD width="3%" noWrap align=center><A HREF="geron33139020-ex991.htm" STYLE="-sec-extract: exhibit"><FONT size=2 face="Times New Roman">99.1</FONT></A></TD>
   <TD width="1%" noWrap align=left><FONT size=2 face="Times New Roman"></FONT></TD>
   <TD width="95%" noWrap align=left><A HREF="geron33139020-ex991.htm" STYLE="-sec-extract: exhibit"><FONT size=2 face="Times New Roman">Press release dated November 1, 2018.</FONT></A></TD></TR></TABLE></DIV>

<P style="TEXT-ALIGN: center"><FONT size=2 face="Times New Roman">1</FONT></P>
<HR align=center SIZE=2 width="100%" noShade>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV>


<P style="TEXT-ALIGN: center"><B><FONT size=2 face="Times New Roman">SIGNATURE</FONT></B></P>
<P STYLE="text-align: left; text-indent: 15pt"><FONT size=2 face="Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly
authorized.</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" BORDER="0" STYLE="line-height: 14pt; border-collapse: collapse; width: 100%">

<TR vAlign=bottom>
   <TD STYLE="text-align: left"></TD>
   <TD COLSPAN="3" STYLE="text-align: left"><FONT size=2 face="Times New Roman">GERON CORPORATION</FONT></TD></TR>
<TR vAlign=bottom>
   <TD STYLE="text-align: left"></TD>
   <TD COLSPAN="3" STYLE="text-align: left">&nbsp;</TD></TR>
<TR vAlign=bottom>
   <TD STYLE="width: 50%; text-align: left"><FONT size=2 face="Times New Roman">Date:&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="Times New Roman">November 1, 2018</FONT></FONT></TD>
   <TD STYLE="width: 3%; text-align: left"><FONT size=2 face="Times New Roman">By:</FONT></TD>
   <TD STYLE="border-bottom: #000000 1pt solid; width: 32%; text-align: left"><FONT size=2 face="Times New Roman">/s/ Stephen N. Rosenfield</FONT></TD>
   <TD STYLE="width: 15%; text-align: left">&nbsp;</TD></TR>
<TR vAlign=bottom>
   <TD STYLE="text-align: left"></TD>
   <TD STYLE="text-align: left"><FONT size=2 face="Times New Roman">Name:&nbsp;&nbsp;</FONT></TD>
   <TD COLSPAN="2" STYLE="text-align: left"><FONT size=2 face="Times New Roman">Stephen N. Rosenfield</FONT></TD></TR>
<TR vAlign=bottom>
   <TD STYLE="text-align: left"></TD>
   <TD STYLE="text-align: left"><FONT size=2 face="Times New Roman">Title:</FONT></TD>
   <TD STYLE="text-align: left; white-space: nowrap"><FONT size=2 face="Times New Roman">Executive Vice President, General Counsel and</FONT></TD>
   <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR vAlign=bottom>
   <TD STYLE="text-align: left"></TD>
   <TD STYLE="text-align: left"></TD>
   <TD COLSPAN="2" STYLE="text-align: left"><FONT size=2 face="Times New Roman">Corporate Secretary</FONT></TD></TR></TABLE>
<P style="TEXT-ALIGN: center"><FONT size=2 face="Times New Roman">2</FONT></P>
<HR align=center SIZE=2 width="100%" noShade>


</BODY>

</HTML>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>geron33139020-ex991.htm
<DESCRIPTION>PRESS RELEASE DATED NOVEMBER 1, 2018
<TEXT>

<HTML>
<HEAD>
   <TITLE></TITLE>
</HEAD>

<BODY bgcolor="#ffffff">


<P style="TEXT-ALIGN: right"><B><FONT size=2 face="Times New Roman">EXHIBIT 99.1 </FONT></B></P>
<P style="TEXT-ALIGN: center"><B><FONT size=2 face="Times New Roman" style="font-variant: small-caps">Press Release Dated November 1, 2018</FONT></B></P>
<IMG border=0 src="geron33139020-ex991x1x1.jpg"> <BR>
<P style="TEXT-ALIGN: center"><B><FONT size=2 face="Times New Roman">Geron Corporation Reports Third Quarter 2018 Financial Results and Recent Company Events</FONT></B></P>

<TABLE style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse; TEXT-ALIGN: left" cellSpacing=0 cellPadding=0 width="100%" border=0>
<TR><TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
<TD vAlign=top width="99%">Imetelstat program transition proceeding, including plans to initiate Phase 3 portion of IMerge<BR>&nbsp;
</TD></TR> <TR> <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
<TD vAlign=top width="99%">Abstracts for IMbark and IMerge accepted for oral presentation at American Society of Hematology Meeting (ASH) in December<BR>&nbsp;</TD></TR> <TR> <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
<TD vAlign=top width="99%">Conference call scheduled for 4:30 p.m. ET today</TD></TR></TABLE>


<P style="TEXT-ALIGN: left"><B><FONT size=2 face="Times New Roman">MENLO PARK, Calif., November 1, 2018 </FONT></B><FONT size=2 face="Times New Roman">-- Geron Corporation (Nasdaq: GERN) today announced recent company events and reported financial
results for the three and nine months ended September 30, 2018. The Company ended the third quarter of 2018 with $184.8 million in cash and marketable securities and expects to utilize these financial resources to advance the clinical development of
imetelstat, the Company&#8217;s first-in-class telomerase inhibitor.</FONT></P>
<P style="TEXT-ALIGN: left"><FONT size=2 face="Times New Roman">&#8220;We are very excited to have 100% ownership of imetelstat, a Phase 3 ready asset with Phase 2 data from both IMerge and IMbark that have been selected for oral presentations at the ASH
meeting in December,&#8221; said John A. Scarlett, M.D., Geron&#8217;s President and Chief Executive Officer. &#8220;We are in the process of transitioning imetelstat back to Geron and have the cash to support our key near-term objective of commencing
enrollment for the Phase 3 portion of IMerge by mid-year 2019.&#8221;</FONT></P>
<P style="TEXT-ALIGN: left"><B><FONT size=2 face="Times New Roman">Recent Company Events</FONT></B></P>
<P style="TEXT-ALIGN: left"><FONT size=2 face="Times New Roman">Geron regained the global rights to develop and commercialize imetelstat upon the termination of a collaboration and license agreement with Janssen Biotech, Inc. (Janssen). The transition of
the entire imetelstat program back to Geron is expected to occur over approximately 12 months, through September 2019, with operational support from Janssen. Patients currently enrolled in the ongoing imetelstat clinical trials in myelofibrosis (IMbark)
and myelodysplastic syndromes (IMerge) will continue to be supported through the respective trial protocols, including treatment and follow-up. Previously, Geron and Janssen shared both the IMerge and IMbark clinical development costs 50/50. While Geron
is now solely accountable for imetelstat development costs, each company will be responsible for their own respective transition costs as the imetelstat program transfers back to Geron.</FONT></P>
<P style="TEXT-ALIGN: left"><FONT size=2 face="Times New Roman">After sponsorship of the imetelstat Investigational New Drug (IND) application has been transferred from Janssen, Geron plans to initiate the Phase 3 portion of IMerge in lower risk
myelodysplastic syndromes (MDS) and is targeting mid-year 2019 for patient screening and enrollment. In addition, Geron intends to discuss the results of the IMbark primary analysis, including the assessment of overall survival as it compares to
historical data, with experts in myelofibrosis (MF), as well as regulatory authorities. The Company believes feedback from these discussions will provide important information on the feasibility, scope and design of any potential future clinical trials
for imetelstat in Intermediate-2 or High-risk MF patients who have relapsed after or are refractory to prior treatment with a JAK inhibitor.</FONT></P>
<P style="TEXT-ALIGN: left"><B><FONT size=2 face="Times New Roman">Third Quarter and Year to Date 2018 Results</FONT></B></P>
<P style="TEXT-ALIGN: left"><FONT size=2 face="Times New Roman">For the third quarter of 2018, the Company reported a net loss of $5.6 million, or $0.03 per share, compared to $6.9 million, or $0.04 per share, for the comparable 2017 period. Net loss for
the first nine months of 2018 was $19.7 million, or $0.11 per share, compared to $20.5 million, or $0.13 per share, for the comparable 2017 period.</FONT></P>
<P style="TEXT-ALIGN: center"><FONT size=2 face="Times New Roman">1</FONT></P>
<HR align=center SIZE=2 width="100%" noShade>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV>


<P style="TEXT-ALIGN: left"><FONT size=2 face="Times New Roman">Revenues for the three and nine months ended September 30, 2018 were $165,000 and $691,000, respectively, compared to $163,000 and $874,000 for the comparable 2017 periods. Revenues for the
three and nine months ended September 30, 2018 and 2017 included royalty and license fee revenues under various non-imetelstat license agreements. The Company adopted the new revenue recognition accounting standard as of January 1, 2018 using the
modified retrospective transition method. Financial results for the three and nine months ended September 30, 2018 are presented under the new accounting standard, but prior period amounts have not been adjusted and continue to be reported under
accounting standards used historically. Therefore, there is a lack of comparability to the prior periods presented. As a result, the decrease in revenues for the nine months ended September 30, 2018, compared to the same period in 2017, reflects not only
a reduction in the number of active non-imetelstat license agreements, but also a change in the accounting method. However, the Company does not expect the adoption of the new revenue recognition accounting standard to have a material impact to its
financial statements on an ongoing basis.</FONT></P>
<P style="TEXT-ALIGN: left"><FONT size=2 face="Times New Roman">Total operating expenses for the three and nine months ended September 30, 2018 were $7.0 million and $22.2 million, respectively, compared to $7.4 million and $22.3 million for the
comparable 2017 periods.</FONT></P>
<P style="TEXT-ALIGN: left"><FONT size=2 face="Times New Roman">Research and development expenses for the three and nine months ended September 30, 2018 were $2.7 million and $8.4 million, respectively, compared to $2.6 million and $8.5 million for the
comparable 2017 periods. The changes in research and development expenses for the three and nine months ended September 30, 2018, compared to the same periods in 2017, primarily reflect the net result of higher personnel related expenses, partially
offset by lower costs for our proportionate share of clinical development expenses under the former imetelstat collaboration with Janssen. Geron expects research and development expenses to increase in the future as Geron&#8217;s share of imetelstat
development costs increases from 50% previously to 100% as of the termination date of the collaboration agreement and as it adds personnel, consultants and a global contract research organization (CRO) to support the further development of
imetelstat.</FONT></P>
<P style="TEXT-ALIGN: left"><FONT size=2 face="Times New Roman">General and administrative expenses for the three and nine months ended September 30, 2018 were $4.3 million and $13.8 million, respectively, compared to $4.8 million and $13.8 million for
the comparable 2017 periods. The decrease in general and administrative expenses for the three months ended September 30, 2018, compared to the same period in 2017, primarily reflects the net result of reduced personnel related expenses, including lower
stock-based compensation expense, partially offset by higher consulting expenses. Geron expects general and administrative expenses to increase in the future with the elimination of cost-sharing with Janssen as of the termination date of the
collaboration agreement for imetelstat patent prosecution expenses and as it adds additional personnel to support the expansion of internal research and development functions.</FONT></P>
<P style="TEXT-ALIGN: left"><FONT size=2 face="Times New Roman">Interest and other income for the three and nine months ended September 30, 2018 was $1.1 million and $2.2 million, respectively, compared to $363,000 and $1.0 million for the comparable
2017 periods. The increase in interest and other income for the three and nine months ended September 30, 2018, compared to the same periods in 2017, primarily reflects higher yields on the Company&#8217;s increased marketable securities
portfolio.</FONT></P>
<P style="TEXT-ALIGN: left"><B><FONT size=2 face="Times New Roman">Conference Call and Webcast</FONT></B></P>
<P style="TEXT-ALIGN: left"><FONT size=2 face="Times New Roman">Geron will host a conference call to discuss third quarter financial results and recent events at 4:30 p.m. ET on Thursday, November 1, 2018.</FONT></P>
<P style="TEXT-ALIGN: left"><FONT size=2 face="Times New Roman">Participants may access the conference call live via telephone by dialing domestically +1 (877) 303-9139 or internationally +1 (760) 536-5195. The passcode is 7133129. A live, listen-only
webcast will also be available on the Company&#8217;s website at www.geron.com/investors/events. If you are unable to listen to the live call, an archived webcast will be available on the Company&#8217;s website for 30 days.</FONT></P>
<P style="TEXT-ALIGN: center"><FONT size=2 face="Times New Roman">2</FONT></P>
<HR align=center SIZE=2 width="100%" noShade>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV>


<P style="TEXT-ALIGN: left"><B><FONT size=2 face="Times New Roman">About Imetelstat</FONT></B></P>
<P style="TEXT-ALIGN: left"><FONT size=2 face="Times New Roman">Imetelstat is a novel, first-in-class telomerase inhibitor exclusively owned by Geron and being developed in hematologic myeloid malignancies. Early clinical data suggest imetelstat may have
disease-modifying activity through the suppression of malignant progenitor cell clone proliferation, which allows potential recovery of normal hematopoiesis. Ongoing clinical studies of imetelstat include a Phase 2/3 trial called IMerge in lower risk
myelodysplastic syndromes (MDS) and a Phase 2 trial called IMbark in Intermediate-2 to High-risk myelofibrosis. Imetelstat received Fast Track designation from the United States Food and Drug Administration for the treatment of patients with
transfusion-dependent anemia due to lower risk MDS who are non-del(5q) and refractory or resistant to an erythroid stimulating agent.</FONT></P>
<P style="TEXT-ALIGN: left"><B><FONT size=2 face="Times New Roman">About Geron</FONT></B></P>
<P style="TEXT-ALIGN: left"><FONT size=2 face="Times New Roman">Geron is a clinical stage biopharmaceutical company focused on the development and potential commercialization of a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid
malignancies. For more information about Geron, visit www.geron.com.</FONT></P>
<P style="TEXT-ALIGN: left"><B><FONT size=2 face="Times New Roman">Use of Forward-Looking Statements</FONT></B></P>
<P style="TEXT-ALIGN: left"><FONT size=2 face="Times New Roman">Except for the historical information contained herein, this press release contains forward-looking statements made pursuant to the &#8220;safe harbor&#8221; provisions of the Private
Securities Litigation Reform Act of 1995. Investors are cautioned that such statements, include, without limitation, those regarding: (i) the prospects for imetelstat; (ii) that more mature data for IMbark and IMerge will be presented at the ASH meeting
in December 2018; (iii) that patient screening and enrollment for the Phase 3 portion of IMerge will begin by mid-year 2019; (iv) that IMbark and IMerge will continue; (v) that there may be a future clinical trial of imetelstat for Intermediate-2 or
High-risk MF patients who are relapsed after or are refractory to prior treatment with a JAK inhibitor; (vi) that adoption of the new revenue recognition accounting standard will not have a material impact on the Company&#8217;s financial statements;
(vii) that imetelstat may have disease-modifying activity; (viii) financial projections and expectations; and (ix) other statements that are not historical facts, constitute forward-looking statements. These statements involve risks and uncertainties
that can cause actual results to differ materially from those in such forward-looking statements. These risks and uncertainties, include, without limitation, risks and uncertainties related to: (i) whether imetelstat will succeed in IMbark and
IMerge--including the Phase 3 portion, by overcoming all of the clinical safety and efficacy, technical, scientific, manufacturing and regulatory challenges and that regulatory authorities permit both trials to continue without any clinical holds; (ii)
Janssen&#8217;s ability to collect additional and more mature data from IMbark and IMerge for an update at ASH; (iii) whether regulatory authorities permit the further development of imetelstat on a timely basis, or at all, to enable patient screening
and enrollment of the Phase 3 portion of IMerge to begin by mid-year 2019; (iv) whether imetelstat is safe and efficacious, and whether any future efficacy or safety results may cause the benefit-risk profile of imetelstat to become unacceptable; (v)
whether the transition of the imetelstat program from Janssen to the Company proceeds on a timely basis to enable patient screening and enrollment of the Phase 3 portion of IMerge to begin by mid-year 2019; (vi) whether experts in MF and regulatory
authorities believe a Phase 3 clinical trial of imetelstat in MF should be initiated; (vii) whether imetelstat does demonstrate disease-modifying activity; (viii) whether adoption of the new revenue recognition accounting standard does not in fact have a
material impact on the Company&#8217;s financial statements; and (ix) the need for future capital. Additional information on the above risks and uncertainties and additional risks, uncertainties and factors that could cause actual results to differ
materially from those in the forward-looking statements are contained in Geron&#8217;s periodic reports filed with the Securities and Exchange Commission under the heading &#8220;Risk Factors,&#8221; including Geron&#8217;s quarterly report on Form 10-Q
for the quarter ended September 30, 2018. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made, and the facts and assumptions underlying the forward-looking statements may change. Except as
required by law, Geron disclaims any obligation to update these forward-looking statements to reflect future information, events or circumstances.</FONT></P>
<P style="TEXT-ALIGN: center"><FONT size=2 face="Times New Roman">3</FONT></P>
<HR align=center SIZE=2 width="100%" noShade>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV>


<P style="TEXT-ALIGN: left"><B><FONT size=2 face="Times New Roman">CONTACT:</FONT></B></P>
<P style="TEXT-ALIGN: left"><FONT size=2 face="Times New Roman">Suzanne Messere<BR></FONT><FONT size=2 face="Times New Roman">Investor and Media Relations <BR>
investor@geron.com<BR>media@geron.com</FONT></P>
<P style="TEXT-ALIGN: left"><FONT size=2 face="Times New Roman">CG Capital <BR>877-889-1972</FONT></P>
<P style="TEXT-ALIGN: left"><FONT size=2 face="Times New Roman">Financial table follows.</FONT></P>
<P style="TEXT-ALIGN: center"><FONT size=2 face="Times New Roman">4</FONT></P>
<HR align=center SIZE=2 width="100%" noShade>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV>


<P style="TEXT-ALIGN: center"><B><FONT size=2 face="Times New Roman">GERON CORPORATION <BR>CONDENSED STATEMENTS OF OPERATIONS<BR></FONT></B><B><FONT size=2 face="Times New Roman">(UNAUDITED)</FONT></B></P>
<TABLE style="LINE-HEIGHT: 14pt; BORDER-COLLAPSE: COLLAPSE" cellSpacing=0 cellPadding=0 width="100%" border=0>

<TR vAlign=bottom>
   <TD width="79%" noWrap align=left></TD>
   <TD width="1%" noWrap align=left></TD>
   <TD width="9%" colSpan=7 noWrap align=center><B><FONT size=2 face="Times New Roman">Three Months Ended</FONT></B></TD>
   <TD width="1%" noWrap align=center></TD>
   <TD width="9%" colSpan=7 noWrap align=center><B><FONT size=2 face="Times New Roman">Nine Months Ended</FONT></B></TD></TR>
<TR vAlign=bottom>
   <TD width="79%" noWrap align=left></TD>
   <TD width="1%" noWrap align=left></TD>
   <TD style="BORDER-BOTTOM: #000000 1pt solid" width="9%" colSpan=7 noWrap align=center><B><FONT size=2 face="Times New Roman">September 30,</FONT></B></TD>
   <TD width="1%" noWrap align=center></TD>
   <TD style="BORDER-BOTTOM: #000000 1pt solid" width="9%" colSpan=7 noWrap align=center><B><FONT size=2 face="Times New Roman">September 30,</FONT></B></TD></TR>
<TR vAlign=bottom>
   <TD width="79%" noWrap align=left><I><FONT size=2 face="Times New Roman">(In thousands, except share and per share data)</FONT></I></TD>
   <TD width="1%" noWrap align=left>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
   <TD style="BORDER-BOTTOM: #000000 1pt solid" width="4%" colSpan=3 noWrap align=center><B><FONT size=2 face="Times New Roman">2018</FONT></B></TD>
   <TD width="1%" noWrap align=center>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
   <TD style="BORDER-BOTTOM: #000000 1pt solid" width="4%" colSpan=3 noWrap align=center><B><FONT size=2 face="Times New Roman">2017</FONT></B></TD>
   <TD width="1%" noWrap align=center>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
   <TD style="BORDER-BOTTOM: #000000 1pt solid" width="4%" colSpan=3 noWrap align=center><B><FONT size=2 face="Times New Roman">2018</FONT></B></TD>
   <TD width="1%" noWrap align=center>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
   <TD style="BORDER-BOTTOM: #000000 1pt solid" width="4%" colSpan=3 noWrap align=center><B><FONT size=2 face="Times New Roman">2017</FONT></B></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
   <TD width="79%" noWrap align=left><FONT size=2 face="Times New Roman">Revenues:</FONT></TD>
   <TD width="1%" noWrap align=left></TD>
   <TD width="1%" noWrap align=left></TD>
   <TD width="2%" noWrap align=left></TD>
   <TD width="1%" noWrap align=left></TD>
   <TD width="1%" noWrap align=left></TD>
   <TD width="1%" noWrap align=left></TD>
   <TD width="2%" noWrap align=left></TD>
   <TD width="1%" noWrap align=left></TD>
   <TD width="1%" noWrap align=left></TD>
   <TD width="1%" noWrap align=left></TD>
   <TD width="2%" noWrap align=left></TD>
   <TD width="1%" noWrap align=left></TD>
   <TD width="1%" noWrap align=left></TD>
   <TD width="1%" noWrap align=left></TD>
   <TD width="2%" noWrap align=left></TD>
   <TD width="1%" noWrap align=left></TD></TR>
<TR vAlign=bottom>
   <TD STYLE="width: 79%; white-space: nowrap; text-align: left; padding-left: 15pt"><FONT size=2 face="Times New Roman">License fees and royalties</FONT></TD>
   <TD width="1%" noWrap align=left><FONT size=2 face="Times New Roman"></FONT></TD>
   <TD width="1%" noWrap align=left><FONT size=2 face="Times New Roman">$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
   <TD width="2%" noWrap align=right><FONT size=2 face="Times New Roman">165</FONT></TD>
   <TD width="1%" noWrap align=left></TD>
   <TD width="1%" noWrap align=left><FONT size=2 face="Times New Roman"></FONT></TD>
   <TD width="1%" noWrap align=left><FONT size=2 face="Times New Roman"><FONT size=2 face="Times New Roman">$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></FONT></TD>
   <TD width="2%" noWrap align=right><FONT size=2 face="Times New Roman">163</FONT></TD>
   <TD width="1%" noWrap align=left></TD>
   <TD width="1%" noWrap align=left><FONT size=2 face="Times New Roman"></FONT></TD>
   <TD width="1%" noWrap align=left><FONT size=2 face="Times New Roman"><FONT size=2 face="Times New Roman">$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></FONT></TD>
   <TD width="2%" noWrap align=right><FONT size=2 face="Times New Roman">691</FONT></TD>
   <TD width="1%" noWrap align=left></TD>
   <TD width="1%" noWrap align=left><FONT size=2 face="Times New Roman"></FONT></TD>
   <TD width="1%" noWrap align=left><FONT size=2 face="Times New Roman"><FONT size=2 face="Times New Roman">$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></FONT></TD>
   <TD width="2%" noWrap align=right><FONT size=2 face="Times New Roman">874</FONT></TD>
   <TD width="1%" noWrap align=left></TD></TR>
<TR vAlign=bottom>
   <TD width="79%" noWrap align=left>&nbsp;</TD>
   <TD width="1%" noWrap align=left><FONT size=2 face="Times New Roman"></FONT></TD>
   <TD width="1%" noWrap align=left><FONT size=2 face="Times New Roman"></FONT></TD>
   <TD width="2%" noWrap align=right><FONT size=2 face="Times New Roman"></FONT></TD>
   <TD width="1%" noWrap align=left></TD>
   <TD width="1%" noWrap align=left><FONT size=2 face="Times New Roman"></FONT></TD>
   <TD width="1%" noWrap align=left><FONT size=2 face="Times New Roman"><FONT size=2 face="Times New Roman"></FONT></FONT></TD>
   <TD width="2%" noWrap align=right><FONT size=2 face="Times New Roman"></FONT></TD>
   <TD width="1%" noWrap align=left></TD>
   <TD width="1%" noWrap align=left><FONT size=2 face="Times New Roman"></FONT></TD>
   <TD width="1%" noWrap align=left><FONT size=2 face="Times New Roman"><FONT size=2 face="Times New Roman"></FONT></FONT></TD>
   <TD width="2%" noWrap align=right><FONT size=2 face="Times New Roman"></FONT></TD>
   <TD width="1%" noWrap align=left></TD>
   <TD width="1%" noWrap align=left><FONT size=2 face="Times New Roman"></FONT></TD>
   <TD width="1%" noWrap align=left><FONT size=2 face="Times New Roman"><FONT size=2 face="Times New Roman"></FONT></FONT></TD>
   <TD width="2%" noWrap align=right><FONT size=2 face="Times New Roman"></FONT></TD>
   <TD width="1%" noWrap align=left></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
   <TD width="79%" noWrap align=left><FONT size=2 face="Times New Roman">Operating expenses:</FONT></TD>
   <TD width="1%" noWrap align=left></TD>
   <TD width="1%" noWrap align=left></TD>
   <TD width="2%" noWrap align=left></TD>
   <TD width="1%" noWrap align=left></TD>
   <TD width="1%" noWrap align=left></TD>
   <TD width="1%" noWrap align=left></TD>
   <TD width="2%" noWrap align=left></TD>
   <TD width="1%" noWrap align=left></TD>
   <TD width="1%" noWrap align=left></TD>
   <TD width="1%" noWrap align=left></TD>
   <TD width="2%" noWrap align=left></TD>
   <TD width="1%" noWrap align=left></TD>
   <TD width="1%" noWrap align=left></TD>
   <TD width="1%" noWrap align=left></TD>
   <TD width="2%" noWrap align=left></TD>
   <TD width="1%" noWrap align=left></TD></TR>
<TR vAlign=bottom>
   <TD STYLE="width: 79%; white-space: nowrap; text-align: left; padding-left: 15pt"><FONT size=2 face="Times New Roman">Research and development</FONT></TD>
   <TD width="1%" noWrap align=left></TD>
   <TD width="1%" noWrap align=left></TD>
   <TD width="2%" noWrap align=right><FONT size=2 face="Times New Roman">2,707</FONT></TD>
   <TD width="1%" noWrap align=left></TD>
   <TD width="1%" noWrap align=left></TD>
   <TD width="1%" noWrap align=left></TD>
   <TD width="2%" noWrap align=right><FONT size=2 face="Times New Roman">2,637</FONT></TD>
   <TD width="1%" noWrap align=left></TD>
   <TD width="1%" noWrap align=left></TD>
   <TD width="1%" noWrap align=left></TD>
   <TD width="2%" noWrap align=right><FONT size=2 face="Times New Roman">8,351</FONT></TD>
   <TD width="1%" noWrap align=left></TD>
   <TD width="1%" noWrap align=left></TD>
   <TD width="1%" noWrap align=left></TD>
   <TD width="2%" noWrap align=right><FONT size=2 face="Times New Roman">8,510</FONT></TD>
   <TD width="1%" noWrap align=left></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
   <TD STYLE="width: 79%; white-space: nowrap; text-align: left; padding-left: 15pt"><FONT size=2 face="Times New Roman">General and administrative</FONT></TD>
   <TD width="1%" noWrap align=left></TD>
   <TD style="BORDER-BOTTOM: #000000 1pt solid" width="1%" noWrap align=left></TD>
   <TD style="BORDER-BOTTOM: #000000 1pt solid" width="2%" noWrap align=right><FONT size=2 face="Times New Roman">4,263</FONT></TD>
   <TD style="BORDER-BOTTOM: #000000 1pt solid" width="1%" noWrap align=left></TD>
   <TD width="1%" noWrap align=left></TD>
   <TD style="BORDER-BOTTOM: #000000 1pt solid" width="1%" noWrap align=left></TD>
   <TD style="BORDER-BOTTOM: #000000 1pt solid" width="2%" noWrap align=right><FONT size=2 face="Times New Roman">4,770</FONT></TD>
   <TD style="BORDER-BOTTOM: #000000 1pt solid" width="1%" noWrap align=left></TD>
   <TD width="1%" noWrap align=left></TD>
   <TD style="BORDER-BOTTOM: #000000 1pt solid" width="1%" noWrap align=left></TD>
   <TD style="BORDER-BOTTOM: #000000 1pt solid" width="2%" noWrap align=right><FONT size=2 face="Times New Roman">13,824</FONT></TD>
   <TD style="BORDER-BOTTOM: #000000 1pt solid" width="1%" noWrap align=left></TD>
   <TD width="1%" noWrap align=left></TD>
   <TD style="BORDER-BOTTOM: #000000 1pt solid" width="1%" noWrap align=left></TD>
   <TD style="BORDER-BOTTOM: #000000 1pt solid" width="2%" noWrap align=right><FONT size=2 face="Times New Roman">13,833</FONT></TD>
   <TD style="BORDER-BOTTOM: #000000 1pt solid" width="1%" noWrap align=left></TD></TR>
<TR vAlign=bottom>
   <TD STYLE="width: 79%; white-space: nowrap; text-align: left; padding-left: 30pt"><FONT size=2 face="Times New Roman">Total operating expenses</FONT></TD>
   <TD width="1%" noWrap align=left></TD>
   <TD style="BORDER-BOTTOM: #000000 1pt solid" width="1%" noWrap align=left></TD>
   <TD style="BORDER-BOTTOM: #000000 1pt solid" width="2%" noWrap align=right><FONT size=2 face="Times New Roman">6,970</FONT></TD>
   <TD style="BORDER-BOTTOM: #000000 1pt solid" width="1%" noWrap align=left></TD>
   <TD width="1%" noWrap align=left></TD>
   <TD style="BORDER-BOTTOM: #000000 1pt solid" width="1%" noWrap align=left></TD>
   <TD style="BORDER-BOTTOM: #000000 1pt solid" width="2%" noWrap align=right><FONT size=2 face="Times New Roman">7,407</FONT></TD>
   <TD style="BORDER-BOTTOM: #000000 1pt solid" width="1%" noWrap align=left></TD>
   <TD width="1%" noWrap align=left></TD>
   <TD style="BORDER-BOTTOM: #000000 1pt solid" width="1%" noWrap align=left></TD>
   <TD style="BORDER-BOTTOM: #000000 1pt solid" width="2%" noWrap align=right><FONT size=2 face="Times New Roman">22,175</FONT></TD>
   <TD style="BORDER-BOTTOM: #000000 1pt solid" width="1%" noWrap align=left></TD>
   <TD width="1%" noWrap align=left></TD>
   <TD style="BORDER-BOTTOM: #000000 1pt solid" width="1%" noWrap align=left></TD>
   <TD style="BORDER-BOTTOM: #000000 1pt solid" width="2%" noWrap align=right><FONT size=2 face="Times New Roman">22,343</FONT></TD>
   <TD style="BORDER-BOTTOM: #000000 1pt solid" width="1%" noWrap align=left></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
   <TD width="79%" noWrap align=left><FONT size=2 face="Times New Roman">Loss from operations</FONT></TD>
   <TD width="1%" noWrap align=left></TD>
   <TD width="1%" noWrap align=left></TD>
   <TD width="2%" noWrap align=right><FONT size=2 face="Times New Roman">(6,805</FONT></TD>
   <TD width="1%" noWrap align=left><FONT size=2 face="Times New Roman">)</FONT></TD>
   <TD width="1%" noWrap align=left></TD>
   <TD width="1%" noWrap align=left></TD>
   <TD width="2%" noWrap align=right><FONT size=2 face="Times New Roman">(7,244</FONT></TD>
   <TD width="1%" noWrap align=left><FONT size=2 face="Times New Roman">)</FONT></TD>
   <TD width="1%" noWrap align=left></TD>
   <TD width="1%" noWrap align=left></TD>
   <TD width="2%" noWrap align=right><FONT size=2 face="Times New Roman">(21,484</FONT></TD>
   <TD width="1%" noWrap align=left><FONT size=2 face="Times New Roman">)</FONT></TD>
   <TD width="1%" noWrap align=left></TD>
   <TD width="1%" noWrap align=left></TD>
   <TD width="2%" noWrap align=right><FONT size=2 face="Times New Roman">(21,469</FONT></TD>
   <TD width="1%" noWrap align=left><FONT size=2 face="Times New Roman">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
   <TD width="79%" noWrap align=left>&nbsp;</TD>
   <TD width="1%" noWrap align=left></TD>
   <TD width="1%" noWrap align=left></TD>
   <TD width="2%" noWrap align=right><FONT size=2 face="Times New Roman"></FONT></TD>
   <TD width="1%" noWrap align=left><FONT size=2 face="Times New Roman"></FONT></TD>
   <TD width="1%" noWrap align=left></TD>
   <TD width="1%" noWrap align=left></TD>
   <TD width="2%" noWrap align=right><FONT size=2 face="Times New Roman"></FONT></TD>
   <TD width="1%" noWrap align=left><FONT size=2 face="Times New Roman"></FONT></TD>
   <TD width="1%" noWrap align=left></TD>
   <TD width="1%" noWrap align=left></TD>
   <TD width="2%" noWrap align=right><FONT size=2 face="Times New Roman"></FONT></TD>
   <TD width="1%" noWrap align=left><FONT size=2 face="Times New Roman"></FONT></TD>
   <TD width="1%" noWrap align=left></TD>
   <TD width="1%" noWrap align=left></TD>
   <TD width="2%" noWrap align=right><FONT size=2 face="Times New Roman"></FONT></TD>
   <TD width="1%" noWrap align=left><FONT size=2 face="Times New Roman"></FONT></TD></TR>
<TR vAlign=bottom>
   <TD width="79%" noWrap align=left><FONT size=2 face="Times New Roman">Interest and other income</FONT></TD>
   <TD width="1%" noWrap align=left></TD>
   <TD width="1%" noWrap align=left></TD>
   <TD width="2%" noWrap align=right><FONT size=2 face="Times New Roman">1,060</FONT></TD>
   <TD width="1%" noWrap align=left></TD>
   <TD width="1%" noWrap align=left></TD>
   <TD width="1%" noWrap align=left></TD>
   <TD width="2%" noWrap align=right><FONT size=2 face="Times New Roman">363</FONT></TD>
   <TD width="1%" noWrap align=left></TD>
   <TD width="1%" noWrap align=left></TD>
   <TD width="1%" noWrap align=left></TD>
   <TD width="2%" noWrap align=right><FONT size=2 face="Times New Roman">2,171</FONT></TD>
   <TD width="1%" noWrap align=left></TD>
   <TD width="1%" noWrap align=left></TD>
   <TD width="1%" noWrap align=left></TD>
   <TD width="2%" noWrap align=right><FONT size=2 face="Times New Roman">1,041</FONT></TD>
   <TD width="1%" noWrap align=left></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
   <TD width="79%" noWrap align=left><FONT size=2 face="Times New Roman">Change in fair value of equity investment</FONT></TD>
   <TD width="1%" noWrap align=left></TD>
   <TD width="1%" noWrap align=left></TD>
   <TD width="2%" noWrap align=right><FONT size=2 face="Times New Roman">205</FONT></TD>
   <TD width="1%" noWrap align=left></TD>
   <TD width="1%" noWrap align=left></TD>
   <TD width="1%" noWrap align=left></TD>
   <TD width="2%" noWrap align=right><FONT size=2 face="Times New Roman">&#8212;</FONT></TD>
   <TD width="1%" noWrap align=left></TD>
   <TD width="1%" noWrap align=left></TD>
   <TD width="1%" noWrap align=left></TD>
   <TD width="2%" noWrap align=right><FONT size=2 face="Times New Roman">(270</FONT></TD>
   <TD width="1%" noWrap align=left><FONT size=2 face="Times New Roman">)</FONT></TD>
   <TD width="1%" noWrap align=left></TD>
   <TD width="1%" noWrap align=left></TD>
   <TD width="2%" noWrap align=right><FONT size=2 face="Times New Roman">&#8212;</FONT></TD>
   <TD width="1%" noWrap align=left></TD></TR>
<TR vAlign=bottom>
   <TD width="79%" noWrap align=left><FONT size=2 face="Times New Roman">Other expense</FONT></TD>
   <TD width="1%" noWrap align=left></TD>
   <TD style="BORDER-BOTTOM: #000000 1pt solid" width="1%" noWrap align=left></TD>
   <TD style="BORDER-BOTTOM: #000000 1pt solid" width="2%" noWrap align=right><FONT size=2 face="Times New Roman">(57</FONT></TD>
   <TD style="BORDER-BOTTOM: #000000 1pt solid" width="1%" noWrap align=left><FONT size=2 face="Times New Roman">)</FONT></TD>
   <TD width="1%" noWrap align=left></TD>
   <TD style="BORDER-BOTTOM: #000000 1pt solid" width="1%" noWrap align=left></TD>
   <TD style="BORDER-BOTTOM: #000000 1pt solid" width="2%" noWrap align=right><FONT size=2 face="Times New Roman">(18</FONT></TD>
   <TD style="BORDER-BOTTOM: #000000 1pt solid" width="1%" noWrap align=left><FONT size=2 face="Times New Roman">)</FONT></TD>
   <TD width="1%" noWrap align=left></TD>
   <TD style="BORDER-BOTTOM: #000000 1pt solid" width="1%" noWrap align=left></TD>
   <TD style="BORDER-BOTTOM: #000000 1pt solid" width="2%" noWrap align=right><FONT size=2 face="Times New Roman">(134</FONT></TD>
   <TD style="BORDER-BOTTOM: #000000 1pt solid" width="1%" noWrap align=left><FONT size=2 face="Times New Roman">)</FONT></TD>
   <TD width="1%" noWrap align=left></TD>
   <TD style="BORDER-BOTTOM: #000000 1pt solid" width="1%" noWrap align=left></TD>
   <TD style="BORDER-BOTTOM: #000000 1pt solid" width="2%" noWrap align=right><FONT size=2 face="Times New Roman">(59</FONT></TD>
   <TD style="BORDER-BOTTOM: #000000 1pt solid" width="1%" noWrap align=left><FONT size=2 face="Times New Roman">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
   <TD width="79%" noWrap align=left><FONT size=2 face="Times New Roman">Net loss</FONT></TD>
   <TD width="1%" noWrap align=left><FONT size=2 face="Times New Roman"></FONT></TD>
   <TD style="BORDER-BOTTOM: #000000 2pt double" width="1%" noWrap align=left><FONT size=2 face="Times New Roman">$</FONT></TD>
   <TD style="BORDER-BOTTOM: #000000 2pt double" width="2%" noWrap align=right><FONT size=2 face="Times New Roman">(5,597</FONT></TD>
   <TD style="BORDER-BOTTOM: #000000 2pt double" width="1%" noWrap align=left><FONT size=2 face="Times New Roman">)</FONT></TD>
   <TD width="1%" noWrap align=left><FONT size=2 face="Times New Roman"></FONT></TD>
   <TD style="BORDER-BOTTOM: #000000 2pt double" width="1%" noWrap align=left><FONT size=2 face="Times New Roman">$</FONT></TD>
   <TD style="BORDER-BOTTOM: #000000 2pt double" width="2%" noWrap align=right><FONT size=2 face="Times New Roman">(6,899</FONT></TD>
   <TD style="BORDER-BOTTOM: #000000 2pt double" width="1%" noWrap align=left><FONT size=2 face="Times New Roman">)</FONT></TD>
   <TD width="1%" noWrap align=left><FONT size=2 face="Times New Roman"></FONT></TD>
   <TD style="BORDER-BOTTOM: #000000 2pt double" width="1%" noWrap align=left><FONT size=2 face="Times New Roman">$</FONT></TD>
   <TD style="BORDER-BOTTOM: #000000 2pt double" width="2%" noWrap align=right><FONT size=2 face="Times New Roman">(19,717</FONT></TD>
   <TD style="BORDER-BOTTOM: #000000 2pt double" width="1%" noWrap align=left><FONT size=2 face="Times New Roman">)</FONT></TD>
   <TD width="1%" noWrap align=left><FONT size=2 face="Times New Roman"></FONT></TD>
   <TD style="BORDER-BOTTOM: #000000 2pt double" width="1%" noWrap align=left><FONT size=2 face="Times New Roman">$</FONT></TD>
   <TD style="BORDER-BOTTOM: #000000 2pt double" width="2%" noWrap align=right><FONT size=2 face="Times New Roman">(20,487</FONT></TD>
   <TD style="BORDER-BOTTOM: #000000 2pt double" width="1%" noWrap align=left><FONT size=2 face="Times New Roman">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
   <TD width="79%" noWrap align=left>&nbsp;</TD>
   <TD width="1%" noWrap align=left><FONT size=2 face="Times New Roman"></FONT></TD>
   <TD width="1%" noWrap align=left><FONT size=2 face="Times New Roman"></FONT></TD>
   <TD width="2%" noWrap align=right><FONT size=2 face="Times New Roman"></FONT></TD>
   <TD width="1%" noWrap align=left><FONT size=2 face="Times New Roman"></FONT></TD>
   <TD width="1%" noWrap align=left><FONT size=2 face="Times New Roman"></FONT></TD>
   <TD width="1%" noWrap align=left><FONT size=2 face="Times New Roman"></FONT></TD>
   <TD width="2%" noWrap align=right><FONT size=2 face="Times New Roman"></FONT></TD>
   <TD width="1%" noWrap align=left><FONT size=2 face="Times New Roman"></FONT></TD>
   <TD width="1%" noWrap align=left><FONT size=2 face="Times New Roman"></FONT></TD>
   <TD width="1%" noWrap align=left><FONT size=2 face="Times New Roman"></FONT></TD>
   <TD width="2%" noWrap align=right><FONT size=2 face="Times New Roman"></FONT></TD>
   <TD width="1%" noWrap align=left><FONT size=2 face="Times New Roman"></FONT></TD>
   <TD width="1%" noWrap align=left><FONT size=2 face="Times New Roman"></FONT></TD>
   <TD width="1%" noWrap align=left><FONT size=2 face="Times New Roman"></FONT></TD>
   <TD width="2%" noWrap align=right><FONT size=2 face="Times New Roman"></FONT></TD>
   <TD width="1%" noWrap align=left><FONT size=2 face="Times New Roman"></FONT></TD></TR>
<TR vAlign=bottom>
   <TD width="79%" noWrap align=left><B><FONT size=2 face="Times New Roman">Basic and diluted net loss per share:</FONT></B></TD>
   <TD width="1%" noWrap align=left></TD>
   <TD width="1%" noWrap align=left></TD>
   <TD width="2%" noWrap align=left></TD>
   <TD width="1%" noWrap align=left></TD>
   <TD width="1%" noWrap align=left></TD>
   <TD width="1%" noWrap align=left></TD>
   <TD width="2%" noWrap align=left></TD>
   <TD width="1%" noWrap align=left></TD>
   <TD width="1%" noWrap align=left></TD>
   <TD width="1%" noWrap align=left></TD>
   <TD width="2%" noWrap align=left></TD>
   <TD width="1%" noWrap align=left></TD>
   <TD width="1%" noWrap align=left></TD>
   <TD width="1%" noWrap align=left></TD>
   <TD width="2%" noWrap align=left></TD>
   <TD width="1%" noWrap align=left></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
   <TD STYLE="width: 79%; white-space: nowrap; text-align: left; padding-left: 15pt"><FONT size=2 face="Times New Roman">Net loss per share</FONT></TD>
   <TD width="1%" noWrap align=left><FONT size=2 face="Times New Roman"></FONT></TD>
   <TD style="BORDER-BOTTOM: #000000 2pt double" width="1%" noWrap align=left><FONT size=2 face="Times New Roman">$</FONT></TD>
   <TD style="BORDER-BOTTOM: #000000 2pt double" width="2%" noWrap align=right><FONT size=2 face="Times New Roman">(0.03</FONT></TD>
   <TD style="BORDER-BOTTOM: #000000 2pt double" width="1%" noWrap align=left><FONT size=2 face="Times New Roman">)</FONT></TD>
   <TD width="1%" noWrap align=left><FONT size=2 face="Times New Roman"></FONT></TD>
   <TD style="BORDER-BOTTOM: #000000 2pt double" width="1%" noWrap align=left><FONT size=2 face="Times New Roman">$</FONT></TD>
   <TD style="BORDER-BOTTOM: #000000 2pt double" width="2%" noWrap align=right><FONT size=2 face="Times New Roman">(0.04</FONT></TD>
   <TD style="BORDER-BOTTOM: #000000 2pt double" width="1%" noWrap align=left><FONT size=2 face="Times New Roman">)</FONT></TD>
   <TD width="1%" noWrap align=left><FONT size=2 face="Times New Roman"></FONT></TD>
   <TD style="BORDER-BOTTOM: #000000 2pt double" width="1%" noWrap align=left><FONT size=2 face="Times New Roman">$</FONT></TD>
   <TD style="BORDER-BOTTOM: #000000 2pt double" width="2%" noWrap align=right><FONT size=2 face="Times New Roman">(0.11</FONT></TD>
   <TD style="BORDER-BOTTOM: #000000 2pt double" width="1%" noWrap align=left><FONT size=2 face="Times New Roman">)</FONT></TD>
   <TD width="1%" noWrap align=left><FONT size=2 face="Times New Roman"></FONT></TD>
   <TD style="BORDER-BOTTOM: #000000 2pt double" width="1%" noWrap align=left><FONT size=2 face="Times New Roman">$</FONT></TD>
   <TD style="BORDER-BOTTOM: #000000 2pt double" width="2%" noWrap align=right><FONT size=2 face="Times New Roman">(0.13</FONT></TD>
   <TD style="BORDER-BOTTOM: #000000 2pt double" width="1%" noWrap align=left><FONT size=2 face="Times New Roman">)</FONT></TD></TR>
<TR vAlign=bottom>
   <TD STYLE="width: 79%; white-space: nowrap; text-align: left; padding-left: 15pt"><FONT size=2 face="Times New Roman">Shares used in computing net loss per share</FONT></TD>
   <TD width="1%" noWrap align=left></TD>
   <TD STYLE="width: 1%; white-space: nowrap; text-align: left; border-bottom: Black 2pt double"></TD>
   <TD STYLE="width: 2%; white-space: nowrap; text-align: right; border-bottom: Black 2pt double"><FONT size=2 face="Times New Roman">184,301,986</FONT></TD>
   <TD STYLE="width: 1%; white-space: nowrap; text-align: left; border-bottom: Black 2pt double"></TD>
   <TD width="1%" noWrap align=left></TD>
   <TD STYLE="width: 1%; white-space: nowrap; text-align: left; border-bottom: Black 2pt double"></TD>
   <TD STYLE="width: 2%; white-space: nowrap; text-align: right; border-bottom: Black 2pt double"><FONT size=2 face="Times New Roman">159,216,642</FONT></TD>
   <TD STYLE="width: 1%; white-space: nowrap; text-align: left; border-bottom: Black 2pt double"></TD>
   <TD width="1%" noWrap align=left></TD>
   <TD STYLE="width: 1%; white-space: nowrap; text-align: left; border-bottom: Black 2pt double"></TD>
   <TD STYLE="width: 2%; white-space: nowrap; text-align: right; border-bottom: Black 2pt double"><FONT size=2 face="Times New Roman">173,187,753</FONT></TD>
   <TD STYLE="width: 1%; white-space: nowrap; text-align: left; border-bottom: Black 2pt double"></TD>
   <TD width="1%" noWrap align=left></TD>
   <TD STYLE="width: 1%; white-space: nowrap; text-align: left; border-bottom: Black 2pt double"></TD>
   <TD STYLE="width: 2%; white-space: nowrap; text-align: right; border-bottom: Black 2pt double"><FONT size=2 face="Times New Roman">159,186,853</FONT></TD>
   <TD STYLE="width: 1%; white-space: nowrap; text-align: left; border-bottom: Black 2pt double"></TD></TR></TABLE>

<P STYLE="text-align: center"><B><FONT size=2 face="Times New Roman">CONDENSED BALANCE SHEETS</FONT></B></P>
<DIV align=center>
<TABLE style="WIDTH: 80%; LINE-HEIGHT: 14pt; BORDER-COLLAPSE: COLLAPSE" cellSpacing=0 cellPadding=0 border=0>

<TR vAlign=bottom>
   <TD width="89%" noWrap align=left></TD>
   <TD width="1%" noWrap align=left></TD>
   <TD width="4%" colSpan=2 noWrap align=center><B><FONT size=2 face="Times New Roman">September 30,</FONT></B></TD>
   <TD width="1%" noWrap align=center></TD>
   <TD width="4%" colSpan=2 noWrap align=center><B><FONT size=2 face="Times New Roman">December 31,</FONT></B></TD></TR>
<TR vAlign=bottom>
   <TD width="89%" noWrap align=left><I><FONT size=2 face="Times New Roman">(In thousands)</FONT></I></TD>
   <TD width="1%" noWrap align=left></TD>
   <TD style="BORDER-BOTTOM: #000000 1pt solid" width="4%" colSpan=2 noWrap align=center><B><FONT size=2 face="Times New Roman">2018</FONT></B></TD>
   <TD width="1%" noWrap align=center></TD>
   <TD style="BORDER-BOTTOM: #000000 1pt solid" width="4%" colSpan=2 noWrap align=center><B><FONT size=2 face="Times New Roman">2017</FONT></B></TD></TR>
<TR vAlign=bottom>
   <TD width="89%" noWrap align=left></TD>
   <TD width="1%" noWrap align=left>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
   <TD width="4%" colSpan=2 noWrap align=center><B><FONT size=2 face="Times New Roman">(Unaudited)</FONT></B></TD>
   <TD width="1%" noWrap align=center>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
   <TD width="4%" colSpan=2 noWrap align=center><B><FONT size=2 face="Times New Roman">(Note 1)</FONT></B></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
   <TD width="89%" noWrap align=left><FONT size=2 face="Times New Roman">Current assets:</FONT></TD>
   <TD width="1%" noWrap align=left></TD>
   <TD width="1%" noWrap align=left></TD>
   <TD width="3%" noWrap align=left></TD>
   <TD width="1%" noWrap align=right></TD>
   <TD width="1%" noWrap align=right></TD>
   <TD width="3%" noWrap align=left></TD></TR>
<TR vAlign=bottom>
   <TD STYLE="width: 89%; white-space: nowrap; text-align: left; padding-left: 15pt"><FONT size=2 face="Times New Roman">Cash, cash equivalents and restricted cash</FONT></TD>
   <TD width="1%" noWrap align=left><FONT size=2 face="Times New Roman"></FONT></TD>
   <TD width="1%" noWrap align=left><FONT size=2 face="Times New Roman">$</FONT></TD>
   <TD width="3%" noWrap align=right><FONT size=2 face="Times New Roman">12,998</FONT></TD>
   <TD width="1%" noWrap align=right><FONT size=2 face="Times New Roman"></FONT></TD>
   <TD width="1%" noWrap align=left><FONT size=2 face="Times New Roman">$</FONT></TD>
   <TD width="3%" noWrap align=right><FONT size=2 face="Times New Roman">16,603</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
   <TD STYLE="width: 89%; white-space: nowrap; text-align: left; padding-left: 15pt"><FONT size=2 face="Times New Roman">Current marketable securities</FONT></TD>
   <TD width="1%" noWrap align=left></TD>
   <TD width="1%" noWrap align=left></TD>
   <TD width="3%" noWrap align=right><FONT size=2 face="Times New Roman">153,622</FONT></TD>
   <TD width="1%" noWrap align=right></TD>
   <TD width="1%" noWrap align=left></TD>
   <TD width="3%" noWrap align=right><FONT size=2 face="Times New Roman">78,351</FONT></TD></TR>
<TR vAlign=bottom>
   <TD STYLE="width: 89%; white-space: nowrap; text-align: left; padding-left: 15pt"><FONT size=2 face="Times New Roman">Other current assets</FONT></TD>
   <TD width="1%" noWrap align=left></TD>
   <TD style="BORDER-BOTTOM: #000000 1pt solid" width="1%" noWrap align=left></TD>
   <TD style="BORDER-BOTTOM: #000000 1pt solid" width="3%" noWrap align=right><FONT size=2 face="Times New Roman">2,254</FONT></TD>
   <TD width="1%" noWrap align=right></TD>
   <TD style="BORDER-BOTTOM: #000000 1pt solid" width="1%" noWrap align=left></TD>
   <TD style="BORDER-BOTTOM: #000000 1pt solid" width="3%" noWrap align=right><FONT size=2 face="Times New Roman">1,016</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
   <TD STYLE="width: 89%; white-space: nowrap; text-align: left; padding-left: 30pt"><FONT size=2 face="Times New Roman">Total current assets</FONT></TD>
   <TD width="1%" noWrap align=left></TD>
   <TD width="1%" noWrap align=left></TD>
   <TD width="3%" noWrap align=right><FONT size=2 face="Times New Roman">168,874</FONT></TD>
   <TD width="1%" noWrap align=right></TD>
   <TD width="1%" noWrap align=left></TD>
   <TD width="3%" noWrap align=right><FONT size=2 face="Times New Roman">95,970</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
   <TD width="89%" noWrap align=left>&nbsp;</TD>
   <TD width="1%" noWrap align=left></TD>
   <TD width="1%" noWrap align=left></TD>
   <TD width="3%" noWrap align=right><FONT size=2 face="Times New Roman"></FONT></TD>
   <TD width="1%" noWrap align=right></TD>
   <TD width="1%" noWrap align=left></TD>
   <TD width="3%" noWrap align=right><FONT size=2 face="Times New Roman"></FONT></TD></TR>
<TR vAlign=bottom>
   <TD width="89%" noWrap align=left><FONT size=2 face="Times New Roman">Noncurrent marketable securities</FONT></TD>
   <TD width="1%" noWrap align=left></TD>
   <TD width="1%" noWrap align=left></TD>
   <TD width="3%" noWrap align=right><FONT size=2 face="Times New Roman">18,143</FONT></TD>
   <TD width="1%" noWrap align=right></TD>
   <TD width="1%" noWrap align=left></TD>
   <TD width="3%" noWrap align=right><FONT size=2 face="Times New Roman">14,241</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
   <TD width="89%" noWrap align=left><FONT size=2 face="Times New Roman">Property and equipment, net</FONT></TD>
   <TD width="1%" noWrap align=left></TD>
   <TD width="1%" noWrap align=left></TD>
   <TD width="3%" noWrap align=right><FONT size=2 face="Times New Roman">66</FONT></TD>
   <TD width="1%" noWrap align=right></TD>
   <TD width="1%" noWrap align=left></TD>
   <TD width="3%" noWrap align=right><FONT size=2 face="Times New Roman">102</FONT></TD></TR>
<TR vAlign=bottom>
   <TD width="89%" noWrap align=left><FONT size=2 face="Times New Roman">Other assets</FONT></TD>
   <TD width="1%" noWrap align=left></TD>
   <TD style="BORDER-BOTTOM: #000000 1pt solid" width="1%" noWrap align=left></TD>
   <TD style="BORDER-BOTTOM: #000000 1pt solid" width="3%" noWrap align=right><FONT size=2 face="Times New Roman">851</FONT></TD>
   <TD width="1%" noWrap align=right></TD>
   <TD style="BORDER-BOTTOM: #000000 1pt solid" width="1%" noWrap align=left></TD>
   <TD style="BORDER-BOTTOM: #000000 1pt solid" width="3%" noWrap align=right><FONT size=2 face="Times New Roman">&#8212;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
   <TD width="89%" noWrap align=left></TD>
   <TD width="1%" noWrap align=left><FONT size=2 face="Times New Roman"></FONT></TD>
   <TD style="BORDER-BOTTOM: #000000 2pt double" width="1%" noWrap align=left><FONT size=2 face="Times New Roman">$</FONT></TD>
   <TD style="BORDER-BOTTOM: #000000 2pt double" width="3%" noWrap align=right><FONT size=2 face="Times New Roman">187,934</FONT></TD>
   <TD width="1%" noWrap align=right><FONT size=2 face="Times New Roman"></FONT></TD>
   <TD style="BORDER-BOTTOM: #000000 2pt double" width="1%" noWrap align=left><FONT size=2 face="Times New Roman">$</FONT></TD>
   <TD style="BORDER-BOTTOM: #000000 2pt double" width="3%" noWrap align=right><FONT size=2 face="Times New Roman">110,313</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
   <TD width="89%" noWrap align=left>&nbsp;</TD>
   <TD width="1%" noWrap align=left><FONT size=2 face="Times New Roman"></FONT></TD>
   <TD width="1%" noWrap align=left><FONT size=2 face="Times New Roman"></FONT></TD>
   <TD width="3%" noWrap align=right><FONT size=2 face="Times New Roman"></FONT></TD>
   <TD width="1%" noWrap align=right><FONT size=2 face="Times New Roman"></FONT></TD>
   <TD width="1%" noWrap align=left><FONT size=2 face="Times New Roman"></FONT></TD>
   <TD width="3%" noWrap align=right><FONT size=2 face="Times New Roman"></FONT></TD></TR>
<TR vAlign=bottom>
   <TD width="89%" noWrap align=left><FONT size=2 face="Times New Roman">Current liabilities</FONT></TD>
   <TD width="1%" noWrap align=left><FONT size=2 face="Times New Roman"></FONT></TD>
   <TD width="1%" noWrap align=left><FONT size=2 face="Times New Roman">$</FONT></TD>
   <TD width="3%" noWrap align=right><FONT size=2 face="Times New Roman">4,467</FONT></TD>
   <TD width="1%" noWrap align=right><FONT size=2 face="Times New Roman"></FONT></TD>
   <TD width="1%" noWrap align=left><FONT size=2 face="Times New Roman">$</FONT></TD>
   <TD width="3%" noWrap align=right><FONT size=2 face="Times New Roman">6,516</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
   <TD width="89%" noWrap align=left><FONT size=2 face="Times New Roman">Stockholders&#8217; equity</FONT></TD>
   <TD width="1%" noWrap align=left></TD>
   <TD style="BORDER-BOTTOM: #000000 2pt double" width="1%" noWrap align=left></TD>
   <TD style="BORDER-BOTTOM: #000000 2pt double" width="3%" noWrap align=right><FONT size=2 face="Times New Roman">183,467</FONT></TD>
   <TD width="1%" noWrap align=right></TD>
   <TD style="BORDER-BOTTOM: #000000 2pt double" width="1%" noWrap align=left></TD>
   <TD style="BORDER-BOTTOM: #000000 2pt double" width="3%" noWrap align=right><FONT size=2 face="Times New Roman">103,797</FONT></TD></TR>
<TR vAlign=bottom>
   <TD width="89%" noWrap align=left></TD>
   <TD width="1%" noWrap align=left><FONT size=2 face="Times New Roman"></FONT></TD>
   <TD style="BORDER-BOTTOM: #000000 2pt double" width="1%" noWrap align=left><FONT size=2 face="Times New Roman">$</FONT></TD>
   <TD style="BORDER-BOTTOM: #000000 2pt double" width="3%" noWrap align=right><FONT size=2 face="Times New Roman">187,934</FONT></TD>
   <TD width="1%" noWrap align=right><FONT size=2 face="Times New Roman"></FONT></TD>
   <TD style="BORDER-BOTTOM: #000000 2pt double" width="1%" noWrap align=left><FONT size=2 face="Times New Roman">$</FONT></TD>
   <TD style="BORDER-BOTTOM: #000000 2pt double" width="3%" noWrap align=right><FONT size=2 face="Times New Roman">110,313</FONT></TD></TR></TABLE></DIV>
<BR>
<TABLE style="LINE-HEIGHT: normal; BORDER-COLLAPSE: COLLAPSE" cellSpacing=0 cellPadding=0 width="100%" border=0>

<TR vAlign=bottom>
   <TD WIDTH="2%" NOWRAP STYLE="text-align: left; vertical-align: top"><B><FONT size=2 face="Times New Roman">Note 1</FONT></B><FONT size=2 face="Times New Roman">:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
   <TD WIDTH="97%" STYLE="text-align: left; vertical-align: top"><FONT size=2 face="Times New Roman">Derived from audited financial statements included in the Company&#8217;s annual report on Form 10-K for the year ended December 31, 2017.</FONT></TD></TR></TABLE>

<P style="TEXT-ALIGN: center"><FONT size=2 face="Times New Roman">###</FONT></P>
<HR align=center SIZE=2 width="100%" noShade>


</BODY>

</HTML>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>geron33139020-ex991x1x1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 geron33139020-ex991x1x1.jpg
M_]C_X  02D9)1@ ! 0$ 70!=  #_[@ .061O8F4 9      !_]L 0P ! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$!_]L 0P$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\  $0@
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MB74;*WO+G0=$^)UA\2?&'A"U\5R6D^F>'/$.AZ/#?"2^U_1=/U+X[_X+?_\
M!R!^P+_P4G_X)E^/?V9O@EX<_:$\,_&/QSXG^$'B6'1_B-X!\,:7X?TE?!_C
MG1?$OB&QO/$N@^/?$4,\L%G8W,=A-:64L5]((=WV7S&6+_0\U32],US3-0T7
M6M.L=7T?5[&[TS5=)U2TM]0TS4]-OX)+6^T_4+"[CFM;VQO+:66WN[2YBE@N
M())(9HWC=E/\8?\ P=0_LQ_\$SOV6O\ @FAXCN/AO^S#^QS\#?VE?BM\6?AI
MI/PMU3X:? OX/> ?BYKEOI?BBV\2?$.[T;4O"7A?2O%47A^W\+Z=>VWBG5H9
MDTGS=4TO1M3N/M6OZ?;78!_0]_P1H_Y1,_\ !-__ +,M_9U_]5AX<K^.#_@F
M_P#MP^ O^"#'_!8[_@J)^SQ_P4"T#Q5\+OAM^U;\7)/&'A+XX/X:\0ZSHVFZ
M-X8^(7QB\6?"?QC+HF@Z9J6LZU\//B=X3^+6H)<>(?#%EKMUX7\4Z59:+JFF
MQPQ^)[WP[_9U_P $BO#NL>%/^"67_!.SP_X@LI=-UG3OV+?V;5O]/N!MN+.:
MX^$WA6[%M<QGYHKF*.X1+B!P'@F$D,@#HP'IO[77_!/S]B_]O/0=%\._M=_L
MZ?#GXX6GAHW7_",:IXGTZZL?%WA>.^>&34+;PQX[\.7NB>-O#MEJ<EM:R:I8
MZ+X@L;/4Y+6U>_@N&MH#& ?Q[7W_  4A\3_\%C/^#B?]B/0/V ?%'QHE_9&_
M96-EKWQ4\:Z-J7Q \(> OB9X<\&:EK'C[Q;XU\9^")SHD6F>#-5U-O#WPK\)
M)X[T>#5]?UF_@$MG#%K&G:=!^_O_  <L?\H0?V\O^Q1^$O\ ZT/\(:_2;]E#
M]A[]DC]AKP9?> ?V2_@#\.O@9X;UB>VNO$ \':0PU[Q3=60G2PNO&'C#59]2
M\7^+[G3X[JYATZ?Q/KNK2Z?!<3063P0R.A]N^)WPL^&7QK\"^(/A?\9/AWX'
M^*_PU\5PV=OXH^'WQ(\*:%XW\$^([?3]2L]8L(-=\+>);'4M$U:&RU;3M/U2
MTCO[&=+?4+&TO(0EQ;0R( ?BC_P;$_\ *#3]A7_L%_'S_P!:G^.%?F__ ,'F
M_P"SEX^^*O\ P3]^"/QM\%:3J6O:5^SC\>);_P"(MEI>GW%Z^B^!_B1X2O\
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MVM[.RL[>&UL[.UACM[6UM;>-8;>VMK>%4B@MX(D2*&&)%CBC541550!/110
64444 %%%% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
